-
Something wrong with this record ?
Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort
J. Burisch, N. Pedersen, S. Cukovic-Cavka, N. Turk, I. Kaimakliotis, D. Duricova, O. Shonová, I. Vind, S. Avnstrøm, N. Thorsgaard, S. Krabbe, V. Andersen, F. Dahlerup Jens, J. Kjeldsen, R. Salupere, J. Olsen, KR. Nielsen, P. Manninen, P. Collin,...
Language English Country United States
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
- MeSH
- Databases, Factual * MeSH
- Adult MeSH
- Inflammatory Bowel Diseases epidemiology therapy MeSH
- Incidence MeSH
- Remission Induction MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Prospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort. METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu). RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe. DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.
Department of Gastroenterology Adelaide and Meath Hospital Trinity College of Dublin Dublin Ireland
Department of Medical Gastroenterology Odense University Hospital Odense Denmark
Department of Medicine 5 Aarhus University Hospital Arhus Denmark
Department of Medicine Amager Hospital Amager Denmark
Department of Medicine Csolnoky F Province Hospital Veszprem Hungary
Department of Medicine Herning Central Hospital Herning Denmark
Division of Endocrinology and Gastroenterology Tartu University Hospital Tartu Estonia
EpiCom Northern Italy Centre based in Crema and Cremona Padova and Reggio Emilia Italy
Gastroenterology Department Hospital České Budějovice České Budějovice Czech Republic
IBD Center ISCARE Charles University Prague Czech Republic
Institute of Regional Health Research University of Southern Denmark Odense Denmark
Medical Department Dronning Ingrids Hospital Nuuk Greenland
Medical Department Hospital of Southern Jutland Aabenraa Denmark
Medical Department The National Hospital of the Faroe Islands Torshavn Faroe Islands
Medical Department Viborg Regional Hospital Viborg Denmark
Nicosia Private Practice Nicosia Cyprus
U O Gastroenterologia Azienda Ospedaliera Università di Padova Padova Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14074498
- 003
- CZ-PrNML
- 005
- 20161026135058.0
- 007
- ta
- 008
- 141006s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/01.MIB.0000436277.13917.c4 $2 doi
- 035 __
- $a (PubMed)24252978
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Burisch, Johan $u 1Medical Section, Digestive Disease Centre, Medical Section, Herlev University Hospital, Copenhagen, Denmark; 2Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia; 3Nicosia Private Practice, Nicosia, Cyprus; 4IBD Center ISCARE, Charles University, Prague, Czech Republic; 5Gastroenterology Department, Hospital České Budějovice, České Budějovice, Czech Republic; 6Department of Medicine, Amager Hospital, Amager, Denmark; 7Department of Medicine, Herning Central Hospital, Herning, Denmark; 8Medical Department, Viborg Regional Hospital, Viborg, Denmark; 9Medical Department, Hospital of Southern Jutland, Aabenraa, Denmark; 10Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark; 11Department of Medicine V (Hepatology and Gastroenterology), Aarhus University Hospital, Arhus, Denmark; 12Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark; 13Division of Endocrinology and Gastroenterology, Tartu University Hospital, Tartu, Estonia; 14Medical Department, The National Hospital of the Faroe Islands, Torshavn, Faroe Islands; 15Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland; 161st Division of Internal Medicine and Hepato-Gastroenterology Unit, University Hospital, Ioannina, Greece; 17Medical Department, Dronning Ingrids Hospital, Nuuk, Greenland; 18Department of Medicine, Csolnoky F. Province Hospital, Veszprem, Hungary; 19Department of Gastroenterology, Adelaide and Meath Hospital, Trinity College of Dublin, Dublin, Ireland; 20Department of Gastroenterology and Hepatology, Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel; 21U.O. Gastroenterologia, Azienda Ospedaliera, Università di Padova, Padova, Italy; 22EpiCom Northern Italy Centre based in Crema & Cremona, Padova and Reggio Emilia, Italy; 23UO Medicina 3° e Gastroenterologia, Azie
- 245 10
- $a Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort / $c J. Burisch, N. Pedersen, S. Cukovic-Cavka, N. Turk, I. Kaimakliotis, D. Duricova, O. Shonová, I. Vind, S. Avnstrøm, N. Thorsgaard, S. Krabbe, V. Andersen, F. Dahlerup Jens, J. Kjeldsen, R. Salupere, J. Olsen, KR. Nielsen, P. Manninen, P. Collin, KH. Katsanos, EV. Tsianos, K. Ladefoged, L. Lakatos, Y. Bailey, C. O'Morain, D. Schwartz, S. Odes, M. Martinato, S. Lombardini, L. Jonaitis, L. Kupcinskas, S. Turcan, L. Barros, F. Magro, D. Lazar, A. Goldis, I. Nikulina, E. Belousova, A. Fernandez, V. Hernandez, S. Almer, Y. Zhulina, J. Halfvarson, HH. Tsai, S. Sebastian, PL. Lakatos, E. Langholz, P. Munkholm, . ,
- 520 9_
- $a BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort. METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu). RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe. DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 12
- $a databáze faktografické $7 D016208
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a idiopatické střevní záněty $x epidemiologie $x terapie $7 D015212
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pedersen, Natalia
- 700 1_
- $a Cukovic-Cavka, Silvja
- 700 1_
- $a Turk, Niksa
- 700 1_
- $a Kaimakliotis, Ioannis
- 700 1_
- $a Duricova, Dana
- 700 1_
- $a Shonová, Olga
- 700 1_
- $a Vind, Ida $7 xx0207519
- 700 1_
- $a Avnstrøm, Søren $7 gn_A_00010378
- 700 1_
- $a Thorsgaard, Niels
- 700 1_
- $a Krabbe, Susanne
- 700 1_
- $a Andersen, Vibeke $7 gn_A_00006098
- 700 1_
- $a Dahlerup Jens, Frederik
- 700 1_
- $a Kjeldsen, Jens
- 700 1_
- $a Salupere, Riina
- 700 1_
- $a Olsen, Jóngerð
- 700 1_
- $a Nielsen, Kári Rubek
- 700 1_
- $a Manninen, Pia
- 700 1_
- $a Collin, Pekka
- 700 1_
- $a Katsanos, Konstantinnos H
- 700 1_
- $a Tsianos, Epameinondas V
- 700 1_
- $a Ladefoged, Karin
- 700 1_
- $a Lakatos, Laszlo
- 700 1_
- $a Bailey, Yvonne
- 700 1_
- $a O'Morain, Colm
- 700 1_
- $a Schwartz, Doron
- 700 1_
- $a Odes, Selwyn
- 700 1_
- $a Martinato, Matteo
- 700 1_
- $a Lombardini, Silvia
- 700 1_
- $a Jonaitis, Laimas
- 700 1_
- $a Kupcinskas, Limas
- 700 1_
- $a Turcan, Svetlana
- 700 1_
- $a Barros, Louisa
- 700 1_
- $a Magro, Fernando
- 700 1_
- $a Lazar, Daniela
- 700 1_
- $a Goldis, Adrian
- 700 1_
- $a Nikulina, Inna
- 700 1_
- $a Belousova, Elena
- 700 1_
- $a Fernandez, Alberto
- 700 1_
- $a Hernandez, Vicent
- 700 1_
- $a Almer, Sven $7 gn_A_00004635
- 700 1_
- $a Zhulina, Yaroslava
- 700 1_
- $a Halfvarson, Jonas
- 700 1_
- $a Tsai, Her-Hsin
- 700 1_
- $a Sebastian, Shaji
- 700 1_
- $a Lakatos, Peter Laszlo
- 700 1_
- $a Langholz, Ebbe
- 700 1_
- $a Munkholm, Pia
- 700 1_
- $a ,
- 773 0_
- $w MED00002243 $t Inflammatory bowel diseases $x 1536-4844 $g Roč. 20, č. 1 (2014), s. 36-46
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24252978 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20141006 $b ABA008
- 991 __
- $a 20161026135513 $b ABA008
- 999 __
- $a ok $b bmc $g 1042381 $s 873410
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 20 $c 1 $d 36-46 $i 1536-4844 $m Inflammatory bowel diseases $n Inflamm Bowel Dis $x MED00002243
- LZP __
- $a Pubmed-20141006
